Effects of resveratrol combined with calcium fructoborate (Fruitex B) in patients with stable angina pectoris

Effects of resveratrol combined with calcium fructoborate (Fruitex B) in patients with stable angina pectoris. A 60 days double-blind-controlled pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN02337806

Enrollment

100

Registered

2010-03-25

Start date

2010-03-30

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable angina pectoris Circulatory System Angina pectoris

Interventions

The study was double-blind and controlled. Patients will be randomised to the following groups 1. Combination of FrxB (120mg) with Resveratrol (10mg) 2. FrxB only 3. Resveratrol only Study drugs will

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female patients = 18 years 2. Diagnosis of angina pectoris (Class II-IV, Canadian Cardiology Society) 3. Informed consent obtained at selection

Exclusion criteria

Exclusion criteria: 1. Unlikely to cooperate in the study 2. Legal incapacity or limited legal incapacity 3. Women who are pregnant, breast-feeding or women of childbearing potential 4. Participation in another drug or device trial at the same time or within the previous 30 days (or within 5 drug half-lives of the investigational drug, or within the time legally required by regulatory authorities, whichever are longer) 5. Known alcohol or drug abuse, known moderate or severe liver disease (Child-Pugh score > 7) or known severe renal disease (serum creatinine > 220 micromoles/L) or known anaemia (blood haemoglobin < 11 g/L)

Design outcomes

Primary

Measure	Time frame
1. Ischemic cardiovascular events 2. The quality of life (Seattle Angina Questionnaire) 3. Serum High-Sensitivity C-Reactive Protein (hsCRP) All outcomes will be assessed at baseline and at the end of the study period (2 months)	—

Secondary

Measure	Time frame
1. Cardiac arrhythmias, assessed by standard transthoracic echocardiography (ECG) 2. Other cardiovascular markers 2.1. Sodium 2.2. Potassium 2.3. Creatinine 2.4. Alanine aminotransferase (ALT) 2.5. Aspartate aminotransferase (AST) 2.6. Fasting plasma glucose 2.7. Total cholesterol 2.8. Low Density Lipoprotein (LDL)-cholesterol 2.9. High Density Lipoprotein (HDL)-cholesterol 2.10. N-terminal prohormone brain natriuretic peptide (NT-proBNP) All outcomes will be assessed at baseline and at the end of the study period (2 months)	—

Measure

Time frame

1. Cardiac arrhythmias, assessed by standard transthoracic echocardiography (ECG) 2. Other cardiovascular markers 2.1. Sodium 2.2. Potassium 2.3. Creatinine 2.4. Alanine aminotransferase (ALT) 2.5. Aspartate aminotransferase (AST) 2.6. Fasting plasma glucose 2.7. Total cholesterol 2.8. Low Density Lipoprotein (LDL)-cholesterol 2.9. High Density Lipoprotein (HDL)-cholesterol 2.10. N-terminal prohormone brain natriuretic peptide (NT-proBNP) All outcomes will be assessed at baseline and at the end of the study period (2 months)

—

Countries

Romania

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026